Gimeno-Hernández Jesus, Iglesias-Moreno Mari-Cruz, Gómez-Serrano Manuel, Carricondo Francisco, Gil-Loyzaga Pablo, Poch-Broto Joaquin
Department of Otolaryngology-Head & Neck Surgery, Hospital Clínico San Carlos, C/ Profesor Martín Lagos s/n, Madrid, Spain.
Acta Otolaryngol. 2011 Aug;131(8):840-6. doi: 10.3109/00016489.2011.564651. Epub 2011 Apr 15.
Abstract Conclusions: In survival analysis, the combined Charlson comorbidity index (CCI) can be considered as a prognostic factor independent of the tumor node metastasis (TNM) classification, tumor stage, and tumor location. Severe comorbidity was the factor that had the greatest impact on prognosis in cases of initial tumor.
To study the influence of comorbidity on the survival of patients undergoing surgery for larynx cancer.
This was a retrospective study of the survival of 231 patients with laryngeal cancer who underwent surgery between 1995 and 2002. The CCI was used to assess comorbidity, the Kaplan-Meier method was used for survival analysis, and the Cox proportional risk regression model was used to identify independent prognostic factors.
The multivariate analysis of specific mortality showed that patients classified as having severe comorbidity (CCI) were more likely to die (adjusted hazard ratio (adjHR) 1.85, 95% confidence interval (CI) 1.07-3.17). This difference was more important in patients with early tumor stages than in those with advanced stages.
摘要结论：在生存分析中，合并Charlson共病指数（CCI）可被视为独立于肿瘤淋巴结转移（TNM）分类、肿瘤分期和肿瘤位置的预后因素。严重共病是对初始肿瘤患者预后影响最大的因素。
研究共病对喉癌手术患者生存的影响。
这是一项对1995年至2002年间接受手术的231例喉癌患者生存情况的回顾性研究。采用CCI评估共病情况，采用Kaplan-Meier方法进行生存分析，采用Cox比例风险回归模型确定独立预后因素。
特异性死亡率的多因素分析显示，被归类为有严重共病（CCI）的患者死亡可能性更大（调整后风险比（adjHR）为1.85，95%置信区间（CI）为1.07 - 3.17）。这种差异在早期肿瘤阶段的患者中比在晚期患者中更为显著。
